Collegium Pharmaceutical touts record 2025, sees JORNAY PM driving 2026 growth at Barclays Miami Conference [Yahoo! Finance]
Collegium Pharmaceutical, Inc. (COLL)
Last collegium pharmaceutical, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.collegiumpharma.com
Company Research
Source: Yahoo! Finance
performance, led by JORNAY PM which grew 48.9% YoY driven by ~20% volume growth, expanded salesforce (125?180 reps) and targeted commercial initiatives. For 2026 the company guided total revenue of $805–$825 million with JORNAY PM expected to reach $190–$200 million (˜31% growth at midpoint) driven primarily by prescription demand, while the pain portfolio is seen as stable but faces pressure from upcoming Nucynta generic dynamics. Collegium generated over $325 million free cash flow in 2025, lowered its cost of capital via a refinancing (SOFR+275), and said it has balance-sheet capacity for ~ $1 billion of transactions while prioritizing BD, opportunistic buybacks, and debt reduction. Interested in Collegium Pharmaceutical, Inc.? Here are five stocks we like better. 5 Hot Stocks With Summer Buybacks You Can Cash In On Collegium Pharmaceutical (NASDAQ:COLL) highlighted a “record-breaking” 2025 and outlined its 2026 outlook at the Barclays Miami Conference, emphasizing strong
Show less
Read more
Impact Snapshot
Event Time:
COLL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COLL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COLL alerts
High impacting Collegium Pharmaceutical, Inc. news events
Weekly update
A roundup of the hottest topics
COLL
News
- Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate Growth Transcript [Seeking Alpha]Seeking Alpha
- Collegium Pharmaceutical to Buy AZSTARYS for $650M, Expanding ADHD Franchise Through 2037 [Yahoo! Finance]Yahoo! Finance
- Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth TrajectoryGlobeNewswire
- A Look At Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Pressure [Yahoo! Finance]Yahoo! Finance
- Collegium Pharmaceutical (COLL) Surged Following Record Quarterly Results [Yahoo! Finance]Yahoo! Finance
COLL
Earnings
- 2/26/26 - Beat
COLL
Sec Filings
- 3/19/26 - Form 8-K
- 3/18/26 - Form 144
- 3/11/26 - Form 4
- COLL's page on the SEC website